Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Microbot Medical Inc. ($MBOT) announced receiving a new patent from the Canadian Intellectual Property Office. The new patent covers the company’s Self-Cleaning Shunt, specifically an inlet head for use on shunts. Microbot has an  exclusive license to the patent from the Technion - Israel Institute of Technology. The news was received positively by the market, where the stock jumped over 68 percent. The company stock has lost over 25 percent of its value this year so far while its 12 months gain stands at 49 percent.
Harel Gadot, CEO, President and Chairman said, “This patent continues to strengthen our IP for the self-cleaning shunt platform and complements the forthcoming US patent that was allowed earlier in the year.“

Avinger ($AVGR) stock soared as the company announced the positive 24 month data from the VISION study assessing the safety and effectiveness of its Pantheris system in performing directional atherectomy while allowing the physician to use real-time intravascular imaging to aid in the removal of plaque from leg arteries. The results show that the follow up on 89 patients showed 82% freedom from target lesion revascularization (TLR) at month 12 by patient (84% by lesion) and 74% freedom from TLR at month 24 by patient (76% by lesion).
The company stock soared by over 19 percent, trimming its Year to Date losses to 85 percent. The stock has lost 95 percent of its value in the past 12 months.

 

AmpilPhi Biosciences ($APHB) announced the appointment of its board member Paul Grint, M.D. as CEO effective immediately. The new appointment replaces Scott Salka who resigned but will continue in a consulting role during the transition.

Concordia International ($CXRX) has been reported that it will be investigated by the UK's Competition and Markets Authority for the potential violation of competition law, specifically the pricing of its 10 mg hydrocortisone between 2013 and 2016.

Jazz Pharmaceuticals ($JAZZ) announced receiving the FDA approval for the Priority Review of its  New Drug Application (NDA) seeking approval of Breakthrough Therapy-tagged VYXEOS (cytarabine and daunorubicin) for the treatment of acute myeloid leukemia. The review status helps to shorten the review clock to six months.

Cytori Therapeutics ($CYTX) announced that the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority  has exercised its rights under Option 2 of its contract with the company for the development of Cytori Cell Therapy (DCCT-10) as an adjunct therapy in thermal burn injury. As per the agreement, BARDA will pay Cytori $13.4 million for reimbursement of development costs plus a fixed fee.

NanoString Technologies ($NSTG) announced inking a new deal for selling 2.75 million shares of its common stock. The stock is being sold to underwriter Robert Baird & Co. and the agreement includes a 30-day option to buy an additional 412.5K shares. The company intends to use the net proceeds for the purpose of funding working capital and general corporate purposes.

EntroMedics ($ETRM) announced its first vBloc implant at AMITA Health Adventist Medical Center in Bolingbrook, IL.. The implant is a pacemaker-like device that delivers vagal nerve blocking therapy via electrodes.

Brokerage
Brokerage Ranking
Action
Company
Rating
Price Target
Impact on Share Price
Jefferies Group LLC
Login to View
Reiterates
Abeona Therapeutics (ABEO)
Buy

N/A
Jefferies Group LLC
Login to View
Reiterates
Align Technology (ALGN)
Buy
$150.00
N/A
Jefferies Group LLC
Login to View
Reiterates
Alere (ALR)
Hold
$51.00
N/A
Jefferies Group LLC
Login to View
Reiterates
Cerner (CERN)
Buy
$74.00
N/A
Jefferies Group LLC
Login to View
Reiterates
DBV Technologies SA - (DBVT)
Buy
$47.00
N/A
Jefferies Group LLC
Login to View
Reiterates
Ra Pharmaceuticals (RARX)
Buy
$25.00
N/A

Gainers (% price change)
Last Trade
Change
Mkt Cap
EXACT Sciences Corp.
EXAS
36.47
+3.82 (11.70%)
3.97B
Depomed Inc
DEPO
10.48
+0.57 (5.75%)
634.76M
The Medicines Company
MDCO
39.77
+2.01 (5.32%)
2.77B
Amicus Therapeutics, Inc.
FOLD
8.02
+0.36 (4.70%)
1.11B
Endologix, Inc.
ELGX
4.82
+0.21 (4.56%)
389.79M
Losers (% price change)

Codexis, Inc.
CDXS
4.00
-0.30 (-6.98%)
192.68M
Endocyte, Inc.
ECYT
2.55
-0.18 (-6.59%)
119.70M
BioCryst Pharmaceuticals
BCRX
5.15
-0.36 (-6.53%)
395.50M
BioDelivery Sciences Intl
BDSI
2.20
-0.15 (-6.38%)
119.18M
Celldex Therapeutics, Inc
CLDX
2.83
-0.17 (-5.67%)
347.10M
Most Actives (dollar volume)

Johnson & Johnson
JNJ
128.25
+1.14 (0.90%)
346.00B
Pfizer Inc.
PFE
32.65
+0.52 (1.62%)
194.37B
C R Bard Inc
BCR
307.43
-2.60 (-0.84%)
22.36B
Regeneron Pharmaceuticals
REGN
459.06
+10.39 (2.32%)
48.10B
Amgen, Inc.
AMGN
155.24
+1.39 (0.90%)
113.31B